Background-Elevated serum cholesterol accounts for a considerable proportion of cardiovascular disease worldwide. An understanding of the relationship between country-level economic and health system factors and elevated cholesterol may provide insight for prioritization of cardiovascular prevention programs. Methods and Results-Using hierarchical models, we examined the relationship between elevated total cholesterol (Ͼ200 mg/dL) in 53 570 outpatients from 36 countries, and tertiles of several country-level indices: (1) gross national income, (2) total expenditure on health as percentage of gross domestic product, (3) government expenditure on health as percentage of total expenditure on health, (4) out-of-pocket expenditures as percentage of private expenditure on health, and the World Health Organization indices of (5) Health System Achievement and (6) Performance/Efficiency. Overall, 38% of outpatients had total cholesterol Ͼ200 mg/dL (Ͼ5.18 mmol/L), and 9.3% of the total variability in elevated cholesterol was at the country level; this proportion was higher for patients with (12.1%) versus without (7.4%) history of hyperlipidemia. Among patients with history of hyperlipidemia, countries in the highest tertile of gross national income or World Health Organization Health System Achievement had lower odds of elevated cholesterol than lower tertiles (PϽ0.001, for both). Countries in the highest tertile of out-of-pocket health expenditures had higher odds of elevated cholesterol than those in the lowest tertile (PϽ0.001). No significant associations were found for patients without history of hyperlipidemia. Conclusions-Global variations in the prevalence of elevated cholesterol among patients with history of hyperlipidemia are associated with country-level economic development and health system indices. These results support the need for strengthening efforts toward effective cardiovascular disease prevention and control and may provide insight for health policy setting at the national level. (Circulation. 2012;125:1858-1869.)
treatment efforts into healthcare policies." According to global estimates from WHO, nearly 1 of every 3 deaths in 2004 was attributed to cardiovascular disease with nearly 80% of these deaths occurring in low-and middle-income countries. 2 In an effort to guide the National Heart, Lung, and Blood Institute in setting priorities for investment in global cardiovascular health, the Institute of Medicine recently outlined key barriers to and evidence-based solutions for the control of cardiovascular disease across the world. 3 An improved understanding of the relationship between levels of national economic development, healthcare investment, health system characteristics, and key modifiable cardiovascular risk factors may provide insights for the prioritization of cardiovascular disease prevention programs.
Clinical Perspective on p 1869
Elevated serum cholesterol is a modifiable risk factor that is associated with an estimated 4.4 million deaths each year and accounts for a considerable proportion of ischemic strokes and heart disease worldwide. 4 Therapeutic lifestyle changes (reduced dietary intake of saturated fats and cholesterol, weight control, and increased physical activity) form the core of all cholesterol-lowering initiatives. Supplemental therapy with lipid-lowering medications has been shown to safely reduce the long-term incidence of major cardiovascular events in secondary prevention and, more recently, high-risk primary prevention trials, and is universally recommended in patients with established or at high predicted risk of cardiovascular disease. 5, 6 Numerous reports have documented the underrecognition and undertreatment of elevated cholesterol levels in developed and developing countries. [7] [8] [9] [10] [11] Whereas most studies have examined the patient-and physician-level factors responsible for these variations, 9, 12, 13, 14 associations with country-level factors have not been systematically explored.
A primary objective of the international Reduction of Atherothrombosis for Continued Health (REACH) Registry 9, 15 was to describe the global distribution and management of risk factors for atherothrombotic events across the spectrum of patients with established atherosclerotic vascular disease. As such, REACH provides a unique source for gaining insight into country-level factors that might influence effective cardiovascular risk factor control. We used data from REACH to examine the relationship between established national indices of overall health system expenditure and performance and country-specific prevalence rates of elevated total cholesterol at baseline. Our analyses allowed the effect of country-level factors to differ for patients with versus without a history of hyperlipidemia, because factors influencing the prevalence of elevated cholesterol may differ between these 2 populations.
Methods

Study Population
The rationale, design, and baseline characteristics of the REACH Registry have been previously published. 9, 15 In brief, REACH is an international, prospective registry of 68 236 outpatients, aged 45 years or older, at risk of atherothrombosis due to established coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD), or Ն3 cardiovascular risk factors. Patients from 39 countries were enrolled between December 2003 to 2004. Presence of established CAD, CVD, and PAD was ascertained by physicians using well-defined criteria (see online-only Data Supplement Methods for definitions). 9 Patients without established CAD, CVD, or PAD could be enrolled given the presence of 3 or more of the following risk factors: treated diabetes mellitus, diabetic nephropathy, ankle-brachial index Ͻ0.9, asymptomatic carotid stenosis Ն70%, carotid intima media thickness that exceeds twice the measure at neighboring sites, systolic blood pressure Ն150 mm Hg despite therapy for at least 3 months, hypercholesterolemia treated with medication, current smoking of at least 15 cigarettes per day, men aged 65 years or older, or women aged 70 years or older. Patients already in a clinical trial, hospitalized patients, or those who might have difficulty returning for a follow-up visit were excluded from enrolment in REACH.
With the goal of yielding a representative sample of patients at the national level, the selection of sites was based on the best available data regarding the burden of atherothrombosis in at-risk populations within each country, and healthcare delivery settings most typically used by those patients. Site characteristics considered in the site selection process included overall patient profiles (eg, CAD, CVD, or PAD, or primary prevention), physician profiles (general practitioners, internists, cardiologists, neurologists, endocrinologists, vascular surgeons), healthcare environments (rural, suburban, urban), and medical practices (office-based, hospital-based). Data for patients enrolled in the registry were collected centrally via use of a standardized international case report form, completed at the study visit. The REACH protocol was submitted to the institutional review board in each country according to local requirements, and signed informed consent was obtained for all patients.
The analysis cohort was derived from the patients enrolled in REACH. Of the 68 236 patients from 39 countries enrolled in REACH, 1576 patients from 3 countries (Taiwan, Hong Kong, and Panama), for which national health system and economic indices were unavailable, were excluded from the current analysis. Of the remaining 66 660 patients, 13 020 (20%) did not have total cholesterol values (16% and 32% of patients with and without a history of hyperlipidemia, respectively), and an additional 70 patients were missing documentation regarding history of hypercholesterolemia. The remaining 53 570 patients (80.4%) from 36 countries formed the analytic cohort for this study.
Elevated Total Blood Cholesterol and History of Hyperlipidemia
Total blood cholesterol levels available at the time of enrollment (measurements must have been taken within the preceding 12 months) were recorded. For this analysis, elevated cholesterol was defined as total cholesterol Ͼ200 mg/dL (Ͼ5.18 mmol/L). 5 History of hyperlipidemia was defined as a documented past diagnosis of hyperlipidemia or reported use of lipid-lowering therapy at study enrollment.
Country-Level Indices
Information on national health expenditures for the year 2001 was obtained from the 2004 World health report 16 for the following indices: total expenditure on health as percentage of gross domestic product (GDP), general government expenditure on health as percentage of total expenditure on health, and out-of pocket expenditure as percentage of private expenditure on health. For country-level income, we used the 2003 gross national income (GNI) per capita (Atlas method) as developed by the World Bank. 17 For country-level data pertaining to health system performance, we used 2 indices developed by WHO: overall Health System Achievement (HAI), and Health System Performance/Efficiency (HPEI). 18 HAI is a weighted linear aggregate of measures of health level, health inequality, responsiveness, responsiveness inequality, and fairness of financial contribution that ranges from 0 to 100, with 100 being the highest possible level of achievement. HPEI is a ratio of the observed level of population health (healthy life expectancy) to the maximum that could be achieved with the observed resources (function of average years of schooling and per capita health expenditure) and ranges 
Statistical Analysis
Baseline characteristics of participants in REACH according to history of hyperlipidemia, both overall and by country, are summarized as means and standard deviations for continuous variables, and percentages for categorical variables. To estimate the proportion of total variability in elevated cholesterol (Ͼ200 mg/dL) that is at the country level, we obtained the intraclass correlation coefficient from a hierarchical logistic regression model in which the individual patient is considered level 1 and country is considered level 2. 20 This analysis was performed for the overall study cohort, and separately for patients with and without history of hyperlipidemia, as well. Cubic smoothing spline models were used to estimate smooth curves describing the associations between country-level health system and economic indices (continuous variables) and countryspecific prevalence of elevated cholesterol. Hierarchical generalized mixed-effects (logistic) regression models, with individual patient at the first level and country (treated as a random effect) at the second level, were used to estimate the association between the countrylevel economic/health system indices and odds of elevated cholesterol. We explored the use of site as a third possible level, but the large number of sites (nϭ5267) and relatively low number of patients per site (mean, 10.2, range,1-20) prohibited model convergence. For these analyses, the national indices of health-related expenditures and performance were categorized into low, medium, and high levels, approximately according to tertiles (see online-only Data Supplement Figure IA through IF) . For GNI per capita, previously established cut points reflecting variation in GNI across countries were used. 21 These analyses were performed on the overall analytic population, with the inclusion of interaction terms between the country-level indices and the indicator for history of hyperlipidemia. Two models were fit for each of the country-level indices, with elevated total cholesterol (Ͼ200 mg/dL) as the outcome measure. The first model adjusted for patient-level factors, assessed at the time of enrollment, including age, sex, educational level, smoking status, obesity (BMI Ն30 kg/m 2 ), established CAD, CVD, or PAD, history of congestive heart failure, carotid surgery, atrial fibrillation/flutter, aortic valve stenosis, diabetes mellitus, and treated hypertension, and current use of antiplatelet and antihypertensive medications; covariates significant at PϽ0.20 were retained in the model. In the second model, we further adjusted for average country-level fat consumption (as continuous variable) 19 to account for the potential influence of regional variation in dietary patterns on cholesterol levels. An interaction between fat consumption and history of hyperlipidemia was also included, and eliminated if nonsignificant (PϾ0.05). From each of the final models, the relative impact of different levels of each health system/economic index on elevated cholesterol was estimated separately for history versus no history of hyperlipidemia subgroups, and associated odds ratios and corresponding 95% confidence limits were generated. All analyses were performed by use of SAS version 9.2 statistical software (SAS Institute Inc, Cary, NC). P values of Յ0.05were considered statistically significant.
Results
In the overall analytic cohort, 20 469 (38%) patients had baseline total cholesterol Ͼ200 mg/dL. The prevalence of elevated cholesterol varied widely across countries and ranged from 73% in Bulgaria to 24% in Finland. Among 42 955 patients with a history of hyperlipidemia, 37% had elevated cholesterol reported at baseline; among the remaining 10 615 patients without history of hyperlipidemia, 43% had elevated cholesterol (Table) . Overall, 9.3% of the total variability in elevated cholesterol was at the country level. This proportion was higher for patients with (12.1%) versus without (7.4%) history of hyperlipidemia. Figure 1A through 1F show scatter plots of the country-level economic/health system indices versus percentage of patients with elevated cholesterol, stratified by history of hyperlipidemia, respectively. For patients with history of hyperlipidemia, country-specific elevated cholesterol percentages tended to increase with decreasing total expenditure on health as percentage of GDP spent on health, GNI, and WHO HAI and PEI indices, and increasing levels of out-of-pocket expenditures. For patients without history of hyperlipidemia, these graphs suggest somewhat different associations, with trends toward high prevalence of elevated cholesterol with both increasing percentage of GDP spent on health and increasing percentage of governmental expenditure as a function of total expenditure on health.
A high prevalence of elevated cholesterol was observed in patients from eastern European countries (Bulgaria. Lithuania, Romania, Ukraine, Hungary, and Russia); these countries also ranked relatively low on health system/economic indices. A relatively low prevalence of elevated cholesterol, similar to that for the United States, was seen for countries (eg, Finland, United Kingdom, Israel, Australia, and Canada) with considerably lower total expenditure on health as percentage of GDP and comparable or slightly more favorable WHO health system indices. Supplement Table I . For the history of hyperlipidemia subgroup, countries in the highest tertile of GNI had significantly lower odds of elevated cholesterol than countries in the lowest tertile (PϽ0.001). Similar results were seen for the WHO HAI. Countries in the lowest tertile of WHO HPEI had significantly higher odds of elevated cholesterol than those in the intermediate or highest tertile (PϽ0.001 for both). Countries in the highest tertile of out-of-pocket health expenditures had significantly higher odds of elevated cholesterol than countries in the lowest tertile (PϽ0.001). No statistically significant associations between country-level factors and odds of elevated cholesterol were found for patients without history of hyperlipidemia.
Higher fat consumption at the country level (average grams per person per day) was associated with a significant increase in the odds of elevated cholesterol in the model examining the association with GNI. For none of the other models was the estimated effect of fat consumption statistically significant, and no significant interactions between fat consumption and history of hyperlipidemia was found in any of the models. As shown in Figure 2A , adjustment for country-level fat consumption in addition to patient-level factors increased the magnitude of association between GNI and the odds of elevated cholesterol. Estimated coefficients for all covariates for both GNI models (with and without fat consumption) are included in the online-only Data Supplement Table II . Estimated coefficients describing the association between patient-level covariates and the odds of elevated cholesterol varied little across models for different country-level indices.
Discussion
The exponential rise in noncommunicable chronic diseases over the past decade has placed a tremendous burden on the health and economic development of countries worldwide, with unprecedented demands for an effective response from governments and other stakeholders in global health. An understanding of how country-level economic and healthcare indices are associated with disease-specific, modifiable risk factors may be of potential value for strategic planning and evaluation of related public health policies and programs. In this study, we examined data from a large, multinational registry of individuals with or at high risk of atherothrombotic events 22, 23 to provide insight into the relationship between indices of national health systems and economic development, and elevated total cholesterol, a key risk factor for cardiovascular disease. The significant associations observed at the country level between these national indices and prevalence of elevated cholesterol underscore the importance for countries to maintain, improve, or establish effective surveillance of chronic disease risk factors such as cholesterol levels, while also prioritizing population-based efforts aimed at the prevention and management of chronic diseases.
Comparison With Previous Studies
Numerous reports have consistently demonstrated a substantial gap between evidence-based guidelines and actual clinical practice across geographic regions, among different physician specialties, and independent of the arterial bed affected. 7,9 -11,13,24 Data from the multinational WHO MONICA Project demonstrated wide variations in the prevalence and treatment of hypercholesterolemia between 1989 and 1997 across 32 populations from 19 countries. 7 Kotseva et al 10 documented dramatic improvements in cholesterol control over time; however, less than half of the patients on lipid-lowering therapy reached the recommended target level. In a recent study of Ϸ80 000 adults from 8 high-and middleincome countries, the proportion of "undiagnosed" individuals with elevated cholesterol (Ն6.2 mmol/L or 240 mg/dL) varied 5-fold (16% in the United States to 78% in Thailand), whereas the rates of effective cholesterol control among patients on lipid-lowering medication ranged from 4% in Germany to 58% in Mexico. 11 In our study, which includes patients from primary care and specialty practices, Ϸ4 in 10 individuals had elevated cholesterol at baseline; this proportion differed significantly across countries, with country-level factors explaining an appreciable proportion of variability in elevated cholesterol in the overall cohort.
Recruitment of patients to the REACH Registry was designed to yield a representative sample of patients, based on the burden of atherothrombosis in at-risk populations within each country and healthcare delivery settings most typically used by those patients. A comparison of the preva-lence of elevated total cholesterol observed in 9 countries included in both the REACH Registry and the EUROASPIRE II survey 25 revealed a high correlation between the 2 studies (rϭ0.72; see online-only Data Supplement Figure II for details). 26 To the extent that the patterns of risk factors observed for patients enrolled in REACH are representative of national patterns for these high-risk populations, findings from our study reveal the degree to which the prevalence of elevated cholesterol at the country level may be related to macroeconomic and healthcare system factors. Moreover, the association between elevated cholesterol and GNI for patients with a history of hypercholesterolemia is consistent with patterns revealed in a recent analysis of data from the multinational Prospective Urban and Rural Epidemiological (PURE) study, 26 in which a 20-fold difference in the use of statins for secondary prevention between low-and highincome countries was found.
The significant associations found between prevalence rates of elevated cholesterol and total and out-of-pocket health expenditures, and WHO indices, as well, for patients 
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with, but not without, a history of hyperlipidemia suggest differential influence of these country-level factors in these patient subsets. Although the exact reasons for these differences cannot be determined in this study, the sample of patients without history of hyperlipidemia in REACH is small (20% of the overall cohort) and likely comprises patients who were either never screened or who had been screened but were found not to be hyperlipidemic before enrollment in the registry. The potential inclusion of the latter category of patient may contribute to the lack of association between the prevalence of elevated cholesterol and country-level indices in this seemingly underdiagnosed subgroup. In contrast, elevated cholesterol in patients with history of hyperlipidemia may be due to prescription of suboptimal therapy (undertreatment) or medication nonadherence related to availability or affordability issues.
Global Challenges for Cholesterol Management
Optimal management of cardiovascular disease is complex and country-level variations in risk factor control may arise from variability in guidelines, and whether, and the extent to which, specific initiatives are effectively implemented, as well. Ferket et al 27 reviewed 27 professional guidelines for cardiovascular risk assessment from Western countries and documented marked differences in the definition of target populations, specific screening tests used, and thresholds for initiating pharmacological treatment. The specific cut point for defining "desirable" cholesterol level varies as do recommended strategies for subsequent risk assessment and management. 5, 6, 28 In our study, based on the National Cholesterol Education Program Adult Treatment Panel III guidelines for risk assessment, 5 we considered total cholesterol Ն200 mg/dL to be elevated. This cut point is, for instance, higher than the thresholds used in guidelines from the European Society of Cardiology 6 and WHO. 28 Such variability in the threshold used to identify elevated cholesterol may explain some of the variation in the prevalence rates of elevated cholesterol across countries and, to the extent that it is correlated with the country-level factors used in this analysis, may underlie some of the associations found. Wide variations in procurement prices across countries and public versus private health sectors have also been demon- strated to impact use of recommended medications across regions. 29 -31 The association between the prevalence of elevated cholesterol and out-of-pocket expenditure seen for patients with history of hyperlipidemia in our study is noteworthy, because it may reflect an inability or unwillingness on the part of some patients in countries with higher out-of-pocket healthcare expenses to be consistently compliant with prescribed chronic lipid-lowering therapy. The recent availability of generic statin therapy should make out-of-pocket expense less of an impediment to use. Recent results from the United States-based Post-Myocardial Infarction Free Rx and Economic Evaluation (MI-FREEE) trial demonstrated that the elimination of copayments for medications prescribed after myocardial infarction significantly improved adherence rates and rates of major cardiovascular events, without increasing overall health costs, although, even with full coverage, adherence rates remained far from optimal, at 55% overall. 32 Barriers to achieving adequate cholesterol control at the population level may also be linked to agricultural and economic policies that increase access to low-cost, unhealthy diets. 33 In our study, adjustment for differences in country-level dietary fat consumption increased the estimated magnitude of association between elevated cholesterol and some country-level indices, suggesting a complex interplay between access to diets rich in highly saturated fats, national level of economic development, and cholesterol levels.
Limitations
Because this analysis was based on data from an observational registry, causal mechanisms underlying the associations described in this report cannot be determined. For example, although the prevalence of elevated cholesterol tended to increase with country-level out-of-of pocket healthcare expenditures, explicit recommendations for national healthcare coverage should not be based on these data alone. Nonetheless, a contemporary study of US outpatients with established CAD found that patients' lack of medical insurance is significantly associated with statin underuse. 14 The summary WHO indices of health system achievement and performance examined in this analysis have drawn criticism relating to the data on and methods by which they were derived. 34, 35 In addition, these indices were derived at an earlier time period than REACH Registry enrolment and may have limited relevance in more contemporary settings. Nevertheless, the observed relationship of these indices to objective disease-specific risk factors in high-risk patients suggests their potential validity for assessing health system performance with respect to effective cardiovascular disease prevention and management.
By design, the REACH Registry recruited participants with access to health care; as a result, the prevalence of elevated cholesterol in this study may underestimate the overall prevalence in the countries included in this study, and the associations found may not be generalizable to individuals without access to medical care. However, these patterns of variation in statin use according to country-level income are similar to those found in the PURE study, 26 which used a community-based sampling scheme.
Total cholesterol measurements were unavailable for proportionately more patients without a history of hyperlipidemia than patients with such history; this was the case for almost all participating countries; and no evidence of systematic differences across countries with respect to other baseline variables was apparent. The extent to which the lower sample size for the no history of hyperlipidemia subgroup, and any systematic bias associated with the availability of total cholesterol measurements, accounts for the lack of significant associations found for that group, cannot be determined. Our models evaluating the association between country-level indices and elevated total cholesterol, however, adjusted for all patient-level risk factors. Other limitations include that fact that information related to lipid-lowering therapy was abstracted from medical records and may not reflect true patient compliance. In addition, details related to dosing strategies, contraindications to the use of, or adverse effects from lipid-lowering medications were not collected in REACH, nor were side effects that may have precluded specific medication use. Finally, whereas other components of the lipoprotein profile might be considered more optimal measures of cardiovascular risk, only total cholesterol measurements were recorded in the REACH Registry.
Implications
The above limitations notwithstanding, these results could serve as impetus for continued national and international dialogue and targeting of efforts toward improving cardiovascular risk factor control. In the past decade, several countries have made progress in their efforts to strengthen national capacity for prevention and control of noncommunicable diseases; yet, much of these advancements are seen in high-income countries. 36 WHO has recently proposed a framework of several cost-effective or low-cost populationbased strategies and individual-level interventions aimed at reducing behavioral and physiological risk factors for chronic diseases that may help reduce such disparities between low/middle-and high-income countries. 1 In recognition of the extent to which patients, physicians, and healthcare systems all influence adherence to preventive therapies, a framework for the integration of healthcare system-based approaches with community-based health promotion efforts within the United States has also been proposed. 37 In addition, as part of the Million Hearts initiative, the US Centers for Medicare and Medicaid Services has expanded coverage for CVD prevention. 38 Efforts such as these, in combination with ensuring adequate infrastructure for surveillance of risk factors and health outcomes, are crucial for controlling the rising, yet preventable, burden of cardiovascular diseases and may serve as a template for other countries to build upon.
Conclusions
Global variations in the prevalence of elevated cholesterol among patients with history of hyperlipidemia are associated with country-level economic and health expenditure indices, and WHO indices of healthcare system achievement and performance/efficiency, as well. These results support the need for maintaining and strengthening healthcare system efforts toward effective cardiovascular disease prevention and control and may provide potential insights for strategic public health policy settings at the national level.
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